Financials data is unavailable for this security.
View more
Year on year Zevra Therapeutics Inc had net income fall 72.00% from a loss of 26.77m to a larger loss of 46.05m despite a 170.26% increase in revenues from 10.16m to 27.46m.
Gross margin | 71.78% |
---|---|
Net profit margin | -274.10% |
Operating margin | -309.83% |
Return on assets | -52.61% |
---|---|
Return on equity | -130.22% |
Return on investment | -65.34% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Zevra Therapeutics Inc fell by 22.42m. Cash Flow from Financing totalled 28.46m or 103.65% of revenues. In addition the company used 33.54m for operations while cash used for investing totalled 17.39m.
Cash flow per share | -1.57 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.7734 |
---|---|
Tangible book value per share | -0.9139 |
More ▼
Balance sheet in USDView more
Current ratio | 2.00 |
---|---|
Quick ratio | -- |
Total debt/total equity | 1.80 |
---|---|
Total debt/total capital | 0.6423 |
More ▼